|First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children|
RTS, S Clinical Trials Partnership
New England Journal of Medicine 365 (20), 1863-1875, 2011
|Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised …|
The Lancet 386 (9988), 31-45, 2015
|Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya|
WP O'Meara, P Bejon, TW Mwangi, EA Okiro, N Peshu, RW Snow, ...
The lancet 372 (9649), 1555-1562, 2008
|Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age|
P Bejon, J Lusingu, A Olotu, A Leach, M Lievens, J Vekemans, S Mshamu, ...
New England Journal of Medicine 359 (24), 2521-2532, 2008
|A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants|
|Upregulation of TGF-β, FOXP3, and CD4+ CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection|
M Walther, JE Tongren, L Andrews, D Korbel, E King, H Fletcher, ...
Immunity 23 (3), 287-296, 2005
|Phase 1 trials of rVSV Ebola vaccine in Africa and Europe|
ST Agnandji, A Huttner, ME Zinser, P Njuguna, C Dahlke, JF Fernandes, ...
New England Journal of Medicine 374 (17), 1647-1660, 2016
|One hundred and twelve infected arthroplasties treated with ‘DAIR’(debridement, antibiotics and implant retention): antibiotic duration and outcome|
I Byren, P Bejon, BL Atkins, B Angus, S Masters, P McLardy-Smith, ...
Journal of Antimicrobial Chemotherapy 63 (6), 1264-1271, 2009
|Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara|
DP Webster, S Dunachie, JM Vuola, T Berthoud, S Keating, SM Laidlaw, ...
Proceedings of the National Academy of Sciences 102 (13), 4836-4841, 2005
|Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure|
A Olotu, G Fegan, J Wambua, G Nyangweso, KO Awuondo, A Leach, ...
New England Journal of Medicine 368 (12), 1111-1120, 2013
|A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants.|
S Rts, ST Agnandji, B Lell, JF Fernandes, BP Abossolo, BG Methogo, ...
The New England journal of medicine 367 (24), 2284-95, 2012
|Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children|
A Olotu, G Fegan, J Wambua, G Nyangweso, A Leach, M Lievens, ...
New England Journal of Medicine 374 (26), 2519-2529, 2016
|Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya|
P Bejon, TN Williams, A Liljander, AM Noor, J Wambua, E Ogada, A Olotu, ...
PLoS Med 7 (7), e1000304, 2010
|Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine|
DE Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, ...
New England Journal of Medicine 373 (21), 2025-2037, 2015
|Oral versus intravenous antibiotics for bone and joint infection|
HK Li, I Rombach, R Zambellas, AS Walker, MA McNally, BL Atkins, ...
New England Journal of Medicine 380 (5), 425-436, 2019
|Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion|
J Illingworth, NS Butler, S Roetynck, J Mwacharo, SK Pierce, P Bejon, ...
The Journal of Immunology 190 (3), 1038-1047, 2013
|Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial|
MT White, R Verity, JT Griffin, KP Asante, S Owusu-Agyei, B Greenwood, ...
The Lancet infectious diseases 15 (12), 1450-1458, 2015
|Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites|
RTS, S Clinical Trials Partnership (2014)
PLoS medicine 11 (7), e1001685, 2014
|Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a …|
A Olotu, J Lusingu, A Leach, M Lievens, J Vekemans, S Msham, T Lang, ...
The Lancet infectious diseases 11 (2), 102-109, 2011
|A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria …|
SJ Dunachie, M Walther, JE Epstein, S Keating, T Berthoud, L Andrews, ...
Infection and immunity 74 (10), 5933-5942, 2006